Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMGN853 · 1 trial · 1 indication
Objective response rate (complete response and partial response rates) by RECIST 1.1 criteria of mirvetuximab soravtansine in patients with folate receptor α-positive persistent or recurrent endometrial cancer
| Arm | Type | Description |
|---|---|---|
| IMGN853 | EXPERIMENTAL | IMGN853 administered 6 mg/kg adjusted ideal body weight (AIBW) once every three weeks (Q3W) |
| Name | Type | Description |
|---|---|---|
| IMGN853 | DRUG | IMGN853 6 mg/kg intravenously every 3 weeks until disease progression |
Inclusion Criteria: * Radiologically confirmed (ie, CT scan and/or MRI) persistent or recurrent endometrial cancer * Patients must have one of the following pathologically documented, definitively diagnosed tumor types: Uterine serous carcinoma (Pure or Mixed), Grade 2 or Grade 3 endometrial adenoc...
Top 20 of 47 competitors
IMGN853 is an investigational small molecule being studied for the treatment of endometrial cancer. It is currently in Phase 2 clinical development, with an active trial evaluating its effects in women with folate receptor-alpha positive endometrial cancer. The drug is not yet approved and remains under investigation.
IMGN853 targets the folate receptor alpha (FRα), a protein that is often overexpressed in certain cancers. By binding to this receptor, the drug is designed to deliver its therapeutic effect specifically to cancer cells that express FRα. This targeted approach is being evaluated in patients with FRα-positive endometrial cancer.
IMGN853 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with endometrial cancer.
IMGN853 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 2 trial is actively recruiting participants to further assess its potential as a treatment for endometrial cancer.
IMGN853 is being studied in a Phase 2 clinical trial with the identifier NCT03832361. This trial, titled 'Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer,' is recruiting 50 female participants aged 18 years and older in the United States.
Yes, IMGN853 is also known as mirvetuximab soravtansine. The clinical trial NCT03832361 uses this alternative name in its title. Both names refer to the same investigational drug being developed by AbbVie for the treatment of folate receptor-alpha positive endometrial cancer.